Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual...
November 03, 2022 09:10 ET | Source: IN8bio, Inc

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML).Clinical activity observed includes continuing robust...
November 01, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at November Investor Conferences

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
September 27, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at Cantor Oncology & HemOnc Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
September 15, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400

Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studiesPotential to expand the agreement to support commercial-scale manufacturing ...
September 13, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
September 08, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
August 30, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio to Present at September Investor and Scientific Conferences

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
August 19, 2022 09:20 ET | Source: IN8bio, Inc

IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
August 16, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...